NEW YORK, April 15, 2015 /PRNewswire/ -- Securities lawyers
at Dunnam & Dunnam are investigating allegations for
Cellular Biomedicine Group Inc. shareholders (NASDAQ: CBMG).
Concerned CBMG investors who purchased shares are encouraged to
contact securities attorney Hamilton Lindley by clicking here.
The law firm's investigation will focus on potential violations
of the federal securities laws by Cellular Biomedicine Group Inc. A
report was published in SeekingAlpha.com on April 7, 2015 stating that (1) Cellular
Biomedicine has achieved an unsustainable $500m valuation by using paid stock promoters;
(2) its "Car-T" technology has experienced patient deaths and is
worthless; (3) its founders have been the target of multiple
allegations of dishonesty; and (4) there are numerous accounting
and financial irregularities in its corporate structure and SEC
filings. Shares of CBMG have fallen, on this news, as much as
$6.30 per share, or more than 24%, to
as low as $25.92 in intraday trading
on April 7, 2015.
Dunnam & Dunnam has significant experience representing
shareholders in securities lawsuits nationwide. CBMG stockholders –
or anyone with knowledge about this situation – should contact
lawyer Hamilton Lindley at hlindley@dunnamlaw.com with questions,
toll free at (844) 702-2990 or visit
http://www.dunnamlaw.com/CBMG.
Find these Waco car accident lawyers on social media on Google+,
LinkedIn, Facebook, and Twitter.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cellular-biomedicine-group-inc-investors-encouraged-to-contact-securities-law-firm-about-investigation-into-allegations-of-corporate-wrongdoing-300066395.html
SOURCE Dunnam & Dunnam